Monetizing QCT via Partnerships

The real upside in QCT is that it can turn BillionToOne from a test seller into an infrastructure supplier for drug developers and other diagnostics companies. Today the company mostly gets paid when a doctor orders a prenatal or oncology assay, but single molecule counting and very low detection limits also fit pharma workflows where the customer pays for assay development, trial support, milestones, and potentially royalties on a companion test tied to a therapy.1 2 3 4 5

• QCT is not just a better readout inside BillionToOne's own lab. The company describes it as a single molecule sequencing platform with absolute quantification, and its filings position the precision and multiplexing of QCT powered assays for problems where standard NGS misses tiny amounts of tumor DNA. That makes it usable as a platform layer in other companies' tests.2 4 5
• The clearest partnership template is biopharma trial work. FDA guidance treats companion diagnostics as tools that are co developed with drugs, and BillionToOne has already signaled this direction through oncology research collaborations and by building tests for therapy selection and response monitoring. In practice, that means helping a drug company identify the right patients and showing earlier whether a treatment is working.3 6 7
• There is a strong economic reason to pursue this. BillionToOne's core business was about $153M in 2024 revenue and roughly $1B in valuation, while larger oncology liquid biopsy peers like Natera and Guardant have won much higher market values by owning clinically embedded cancer testing workflows. Licensing or co development would let BillionToOne monetize QCT without carrying every sales and reimbursement battle alone.1 8 9

The next step is likely more oncology deals where QCT is packaged as the measurement engine behind MRD, treatment monitoring, and drug linked diagnostics. If BillionToOne proves that its sensitivity changes trial design or gets drugs to market faster, platform revenue can compound alongside its own testing business and make the company more valuable than a stand alone lab.3 4 5 6 7